Operating Expenses
Regeneron Pharmaceuticals·Income Statement·4 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total costs & expenses | $2.5B | $2.5B | $2.8B | $2.4B | $2.6B | $2.7B | $3B | $3B |
| Research and development | $1.2B | $1.3B | $1.4B | $1.3B | $1.4B | $1.5B | $1.6B | $1.5B |
| Selling, general and administrative | $758.8M | $714.4M | $792.2M | $633M | $634.2M | $657.8M | $775M | $647.7M |
| Acquired in-process research and development | $23.9M | $56.2M | $13.8M | $12.3M | $10M | $83.1M | $18.7M | $101.9M |